血浆游离DNA中抑癌基因肿瘤高甲基化基因1甲基化检测方法的建立及其在乳腺疾病诊断中的意义

doi:10.16150/j.1671-2870.2019.02.005

摘要/Abstract

摘要：

目的：通过建立血浆游离DNA中肿瘤高甲基化基因1（hypermethylated in cancer 1, HIC-1）甲基化检测技术，评估其作为体液活检诊断方法在乳腺良恶性疾病鉴别中的价值。方法：收集35份乳腺疾病患者（其25例乳腺癌，10例乳腺良性疾病）及10份健康志愿者的血液样本，分离、提取血浆中的游离DNA。采用亚硫酸氢盐测序（bisulfite sequencing PCR，BSP）法，检测HIC-1基因启动子区域-636~-424 bp中16个CpG位点的甲基化水平。结果：在检测的16个CpG位点中，以-636~-617 bp中的4个位点甲基化最为明显。其中，乳腺癌组的这4个位点平均甲基化率为22.6%，而良性乳腺疾病组为8.5%，健康对照组为8.3%，3组间的差异有统计学意义（P<0.05）。进一步绘制受试者工作特征曲线（receiver operator characteristic curve, ROC曲线）进行分析，发现以这4个位点的平均甲基化率诊断乳腺癌时，其曲线下面积（area under the cure AUC）为0.794，证实其对乳腺癌具有一定的诊断价值。结论：检测血浆游离DNA中抑癌基因HIC-1启动子区甲基化水平，在乳腺癌诊断中有一定参考价值。

关键词: 乳腺癌, 抑癌基因, HIC-1, 甲基化检测, 血浆游离DNA

Abstract:

Objective: To establish a detection method for gene hypermethylated in cancer 1（HIC-1） methylation in cell-free DNA in peripheral blood and to evaluate its significance in diagnosis of benign and malignant breast tumors. Methods: The cell free DNA was extracted from 45 blood samples including breast disease patients and healthy volunteers. These DNA were treated with bisulfite and using Bisulfite Sequencing PCR(BSP) method to detect the methylation level of the 16 CpG sites in HIC-1 gene promoter region -636—-424 bp. Results: Of the breast cancer group, the methylation trend was obvious among the 4 sites in -636—-617 bp. Its average methylation rate was 22.6%. Frequency of methylation of HIC-1 gene promoter region was significantly higher in 25 patients with breast cancer compared with that in 10 benign tumor samples (22.6% vs 8.5%, P<0.05) and 10 healthy control samples (22.6% vs 8.3%, P<0.05). The ROC curve analysis showed that the area under curve（AUC） was 0.794, indicating a certain diagnostic value for breast cancer. Conclusions: The detection of HIC-1 gene promoter methylation in cell-free DNA has certain clinical significance in the diagnosis of breast cancer.

Key words: Breast cancer, Tumor suppressor gene, Hypermethylated in cancer 1, Methylation detection, Cell-free DNA

中图分类号:

R737.41

钟明, 赵峰, 吴衍, 裴文江, 高航, 郭善禹, 戴谦诚, 张伟. 血浆游离DNA中抑癌基因肿瘤高甲基化基因1甲基化检测方法的建立及其在乳腺疾病诊断中的意义[J]. 诊断学理论与实践, 2019, 18(2): 144-148.

ZHONG Ming, ZHAO Feng, WU Yan, PEI Wenjiang, GAO Hang, GUO Shanyu, DAI Qiancheng, ZHANG Wei. Establishment of a detection method for tumor suppressor gene HIC-1 methylation in cell-free DNA and its significance in diagnosis of breast diseases[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(2): 144-148.

图/表 5

图1

图2

图3

图4

表1

参考文献 19

[1]	Allemani C, Matsuda T, di Carlo V, et al. Global surveillance of trends in cancer survival 2000- 14(CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125):1023-1075.
[2]	Bae YK, Shim YR, Choi JH, et al. Gene promoter hypermethylation in tumors and plasma of breast cancer patients[J]. Cancer Res Treat, 2005, 37(4):233-240.
[3]	Agostini M, Enzo MV, Bedin C, et al. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients[J]. Cancer Biomark, 2012, 11(2-3):89-98.
[4]	Han ZH, Xu CS, Han H, et al. Value of the level of methylation of RASSF1A and WIF-1 in tissue and serum in neoadjuvant chemotherapeutic assessment for advanced breast cancer[J]. Oncol Lett, 2017, 14(4):4499-4504.
[5]	Fu D, Ren C, Tan H, et al. Sox 17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer[J]. Medicine (Baltimore), 2015, 94(11):e637
[6]	Parrella P, Scintu M, Prencipe M, et al. HIC 1 promoter methylation and 17p13.3 allelic loss in invasive ductal carcinoma of the breast[J]. Cancer Lett, 2005, 222(1):75-81.
[7]	Yamanaka M, Watanabe M, Yamada Y, et al. Altered methylation of multiple genes in carcinogenesis of the prostate[J]. Int J Cancer, 2003, 106(3):382-387.
[8]	Kanai Y, Ushijima S, Ochiai A, et al. DNA hypermethylation at the D17S5 locus is associated with gastric carcinogenesis[J]. Cancer Lett, 1998, 122(1-2):135-141.
[9]	裴文江, 赵峰, 吴衍, 等. 肿瘤高甲基化基因1重要下游基因HMMR对乳腺癌细胞株MDA-MB-231迁移和侵袭能力影响的体外实验[J]. 诊断学理论与实践, 2018, 17(1):70-75.
[10]	Rasti M, Tavasoli P, Monabati A, et al. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients[J]. Iran Biomed J, 2009, 13(4):199-206.
[11]	Rathi A, Virmani AK, Harada K, et al. Aberrant methylation of the HIC1 promoter is a frequent event in speci-fic pediatric neoplasms[J]. Clin Cancer Res, 2003, 9(10 Pt 1):3674-3678.
[12]	Narayan G, Arias-Pulido H, Koul S, et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome[J]. Mol Cancer, 2003, 2:24.
[13]	Garcia JM, Silva JM, Dominguez G, et al. Heterogeneous tumor clones as an explanation of discordance between plasma DNA and tumor DNA alterations[J]. Genes Chromosomes Cancer, 2001, 31(3):300-301.
[14]	Zhang W, Zeng X, Briggs KJ, et al. A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1[J]. Oncogene, 2010, 29(17):2467-2476.
[15]	Wang Y, Weng X, Wang L, et al. HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk[J]. J Clin Invest, 2018, 128(12):5235-5250.
[16]	Skvortsova TE, Rykova EY, Tamkovich SN, et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation[J]. Br J Cancer, 2006, 94(10):1492-1495.
[17]	Hernández HG, Tse MY, Pang SC, et al. Optimizing methodologies for PCR-based DNA methylation analysis[J]. Biotechniques, 2013, 55(4):181-197.
[18]	陈卫中, 倪宗瓒, 潘晓平, 等. 用ROC曲线确定最佳临界点和可疑值范围[J]. 现代预防医学, 2005, 32(7):729-731.
[19]	Kumar R, Indrayan A. Receiver operating characteristic (ROC) curve for medical researchers[J]. Indian Pediatr, 2011, 48(4):277-287.

指标	例数(n)	甲基化频率(%)	P值
年龄（岁） ≥50 <50	18	23±14 22±16	0.961
肿瘤直径 ≥2 cm <2 cm	15 10	21±15 24±14	0.610
临床分期 Ⅰ+Ⅱ Ⅲ+Ⅳ	22 3	22±13 23±25	0.921
腋窝淋巴结阳性阴性	5 20	27±19 21±13	0.419
ER 阳性阴性	19 6	21±14 26±17	0.476
PR 阳性阴性	18 7	21±14 26±16	0.499
HER2 阳性阴性	11 14	18±13 26±14	0.155